Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:361408rdf:typepubmed:Citationlld:pubmed
pubmed-article:361408lifeskim:mentionsumls-concept:C0025007lld:lifeskim
pubmed-article:361408lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:361408lifeskim:mentionsumls-concept:C0014038lld:lifeskim
pubmed-article:361408lifeskim:mentionsumls-concept:C0234428lld:lifeskim
pubmed-article:361408lifeskim:mentionsumls-concept:C0023570lld:lifeskim
pubmed-article:361408lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:361408pubmed:issue5lld:pubmed
pubmed-article:361408pubmed:dateCreated1979-1-26lld:pubmed
pubmed-article:361408pubmed:abstractTextResults are reported of a double-blind trial with L-dopa in 39 patients with measles encephalitis. In this treatment series, L-dopa improved the state of awareness and the diffuse disturbances in the EEG. There was a significant difference too, regarding the outcome between patients treated with L-dopa and placebo. The death rate in the L-dopa-treated group was lower and there were fewer mental sequelae. It is suggested, that L-dopa should be used in patients with measles encephalitis.lld:pubmed
pubmed-article:361408pubmed:languageenglld:pubmed
pubmed-article:361408pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:361408pubmed:citationSubsetIMlld:pubmed
pubmed-article:361408pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:361408pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:361408pubmed:statusMEDLINElld:pubmed
pubmed-article:361408pubmed:issn0014-3022lld:pubmed
pubmed-article:361408pubmed:authorpubmed-author:ChandraBBlld:pubmed
pubmed-article:361408pubmed:issnTypePrintlld:pubmed
pubmed-article:361408pubmed:volume17lld:pubmed
pubmed-article:361408pubmed:ownerNLMlld:pubmed
pubmed-article:361408pubmed:authorsCompleteYlld:pubmed
pubmed-article:361408pubmed:pagination265-70lld:pubmed
pubmed-article:361408pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-H...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-A...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-M...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-C...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-C...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-E...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-C...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-P...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-F...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-M...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-E...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-C...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-D...lld:pubmed
pubmed-article:361408pubmed:meshHeadingpubmed-meshheading:361408-L...lld:pubmed
pubmed-article:361408pubmed:year1978lld:pubmed
pubmed-article:361408pubmed:articleTitleTreatment of disturbances of consciousness caused by measles encephalitis with levodopa.lld:pubmed
pubmed-article:361408pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:361408pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:361408pubmed:publicationTypeControlled Clinical Triallld:pubmed